Evotec And Indivumed Announce Strategic Drug Discovery Collaboration On Precision Medicine For Colorectal Cancer

Evotec And Indivumed Announce Strategic Drug Discovery Collaboration On Precision Medicine For Colorectal Cancer

Publication date: Apr 11, 2019

(MENAFN – ACCESSWIRE ) The collaboration leverages Indivumed’s true multi-omics cancer database “IndivuType” and Evotec’s drug discovery platforms to identify new therapeutics for colorectal cancer HAMBURG, GERMANY / ACCESSWIRE / April 11, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH announced today that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”).

The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary bioinformatics analysis platform “PanHunter” as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed’s true multi-omics cancer database “IndivuType”.

Indivumed’s commitment to generating high quality and extensive cancer patient data is synergistic to Evotec’s expertise in analysing multi-omics data and developing novel platforms to aid the discovery of first-in-class clearly differentiated small molecule and antibody therapeutics.

Under the terms of the agreement, Evotec has made an undisclosed upfront payment to Indivumed for access to the CRC patient cohort of the IndivuType database.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: “Evotec is very pleased to partner with Indivumed, who is truly dedicated to developing precision medicine in oncology by generating the most comprehensive multi-omics patient database in oncology that is differentiated from previous datasets due to the higher patient numbers and the application of rigorous quality standards.

Prof. Dr Hartmut Juhl, Chief Executive Officer of Indivumed, said: “IndivuType is the only true multi-omics database available in the world, enabling break-through insights that lead to new cancer solutions.

Our partnership with Evotec fits well with realising our vision of using the multi-omics data within IndivuType to generate new precision medicine therapeutics.

About IndivuType IndivuType, the world’s first true multi-omics database for individualised cancer therapy uses the highest quality cancer biospecimens that ultimately produces highest quality data to enable novel discoveries in cancer biology in the post-genomics era.

Concepts Keywords
Antibody Cancer
Asia Personalised healthcare www
Australia Media contactCorrine
Bayer Drug solutions
Biobank Proteomics
Biomarkers Genomics
Biotechnology Evotec
Boehringer Ingelheim Life sciences
Cancer Medicine
Celgene Branches of biology
Chief Executive Officer Transcriptomics
Clinical Trials Biotechnology
Cohort Drug discovery
Colon Proteomics
Colorectal Cancer Genomics
Diabetes Antibody
DNA Biomarker
Drug Discovery Sanofi
Eastern Europe
Ecosystem
Fibrosis
Forge
Frankfurt Stock Exchange
Genomics
Germany
GERMANY
Hamburg
Healthcare
Incidence
Infectious Diseases
Inflammation
ISIN
Live Wire
Malignancy
MDAX
Metastatic
Mortality
Novartis
Novo Nordisk
Omics
Oncology
Pain
Patient Advocacy
Perioperative
Pfizer
Pharmaceutical
Phenotype
Phenotypes
Pipeline
Proteomics
Protocol
Rectum
RNA
Sanofi
Small Molecule
SOP
South America
Stratification
Synergistic
Takeda
Transcriptomics
Twitter

Semantics

Type Source Name
disease MESH Colorectal Cancer
disease DOID Colorectal Cancer
pathway BSID Colorectal cancer
disease MESH multi
disease MESH cancer
disease DOID cancer
gene UNIPROT ANP32B
gene UNIPROT TNFSF13
drug DRUGBANK Nonoxynol-9
gene UNIPROT AICDA
gene UNIPROT WDFY2
disease MESH risk factors
gene UNIPROT SLC35G1
gene UNIPROT ESR1
gene UNIPROT ERAL1
gene UNIPROT PTPN5
drug DRUGBANK Coenzyme M
gene UNIPROT WIPF2
disease MESH development
gene UNIPROT THOP1
gene UNIPROT AGRP
gene UNIPROT ARTN
disease MESH complications
disease MESH inflammation
disease MESH infectious diseases
disease MESH fibrosis
disease MESH multiple
gene UNIPROT SET
pathway BSID Release

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *